Blunted humoral response after mRNA vaccine in patients with haematological malignancies
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Patients with haematological malignancies are at a higher risk for severe COVID-19 outcomes than healthy individuals. These patients can also have long-term direct and indirect clinical consequences of SARS-CoV-2 infection, including stalled cancer care. Therefore, to reduce the impact of COVID-19 on this clinically vulnerable population, optimal vaccine protection is paramount. The COVID-19 mRNA vaccines produce a robust adaptive immune response in healthy individuals and have been a tremendous success in real-world conditions. However, the pivotal mRNA vaccine trials excluded patients with cancer who were on active treatment. As such, little information is available about vaccine efficacy in patients with haematological malignancies. Among patients with haematological malignancies, vaccine-induced immunity is generally subdued and depends on the type of cancer and its treatment, as well as the immunogenicity of the specific vaccine. Responses to traditional influenza and pneumococcal immunisation are inadequate, especially in haematopoietic stem-cell transplantation (HSCT) recipients or after B-cell depleting therapies such as Bruton's tyrosine kinase inhibitors (BTKIs) or anti-CD20 antibodies.
The Lancet Haematology , commentaire en libre accès, 2020